OOIR: Observatory of International Research

Papers

(The H4-Index of Immunology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
New‐onset autoimmune phenomena post‐COVID‐19 vaccination	333
Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease	107
Haemocyte‐mediated immunity in insects: Cells, processes and associated components in the fight against pathogens and parasites	86
Cytokine‐regulated Th17 plasticity in human health and diseases	70
The NLRP6 inflammasome	70
The role of Bruton's tyrosine kinase in the immune system and disease	62
NK‐cell exhaustion, B‐cell exhaustion and T‐cell exhaustion—the differences and similarities	57
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function	55
NLRP7: From inflammasome regulation to human disease	51
Neutrophil and remnant clearance in immunity and inflammation	50
Single‐cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer	47
Endocannabinoids in immune regulation and immunopathologies	43
Human FOXP3 and tumour microenvironment	43
Retinal microglia: Functions and diseases	42
Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages	39
Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment	38
Crosstalk between B cells and neutrophils in rheumatoid arthritis	35
B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy	35
Macrophage reprogramming for therapy	35
Development of a high‐sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS‐CoV‐2 spike glycoprotein in serum and saliva	33
NLR in eXile: Emerging roles of NLRX1 in immunity and human disease	32
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo‐controlled trial	31
CD8⁺ T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy	31
Double‐negative T cells: Setting the stage for disease control or progression	31
Siglec‐5 is an inhibitory immune checkpoint molecule for human T cells	30

Vaccines, adjuvants and key factors for mucosal immune response	30
Neutrophil–T cell crosstalk in inflammatory bowel disease	29
Emerging roles of extracellular vesicles in COVID‐19, a double‐edged sword?	29